Orrick Represents Shore Capital in RedX Pharma IPO
Orrick, Herrington & Sutcliffe (Europe) LLP represented Shore Capital as nominated adviser and broker to RedX Pharma on its initial public offering on London’s Alternative Investment Market (AIM).
RedX has raised £15 million and is valued at about £55.2 million on admission. It is a drug development company formed in 2010 that is focused on improving the characteristics of drugs in the areas of cancer and infectious disease.